Xilio Therapeutics Inc. (XLO) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Xilio Therapeutics Inc. (NASDAQ: XLO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $7.77 (-3.00% 1D, market cap $51.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XLO ranks #928 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XLO carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GANX (Gain Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $51.9M) and IBIO (iBio Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $52.3M). Among the 5-stock peer group, XLO leads on earnings multiple (N/A) while XLO leads on capital efficiency (-35.0% ROIC).
Per XLO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840233), Xilio Therapeutics Inc. generated $43.8M in revenue (+589.9% YoY), -$35.0M in net income, and -$5.5M in free cash flow against $154.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 42.1 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While XLO currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.80) and Max Pain ($8.16) forces dealer call-delta covering toward $12.94.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Xilio Therapeutics Inc. (XLO) dropped -3.00% to $7.77, trading at 22% of its 52-week range ($6.47 – $12.32). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors Anticipate reporting initial Phase 1 data in the fourth quarter of 2027 Plan to present a tr
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that the first patient has been
Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XLO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XLO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Xilio Therapeutics Inc. (XLO) ranks #928 by composite RQD confidence (27/100, grade E) and #748 by equity capitalization ($51.1M). Within this direct 5-issuer industry benchmark cohort, XLO leads on earnings valuation at N/A trailing P/E, while XLO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GANX currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with XLO at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XLO
ACTIVE
Xilio Therapeutics Inc. | E | 27/100 | — | — | -35.0% | -3.00% | $51.1M | Benchmark Subject |
| GANX Gain Therapeutics Inc. | D- | 41/100 | — | — | -35.0% | -0.42% | $51.9M | /ganx-vs-xlo → |
| IBIO iBio Inc. | E | 23/100 | — | — | -35.0% | +1.17% | $52.3M | /ibio-vs-xlo → |
| CNTB Connect Biopharma Holdings Limited | D- | 35/100 | — | — | -35.0% | -1.17% | $52.6M | /cntb-vs-xlo → |
| CTOR Citius Oncology Inc. | E | 34/100 | — | — | -35.0% | -8.20% | $49.2M | /ctor-vs-xlo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xilio Therapeutics Inc. (XLO) reported GAAP revenue of $43.8M (+589.9% vs. FY2024 revenue of $6.3M ) , GAAP net income of -$35.0M, operating cash flow of -$5.0M, and free cash flow of -$5.5M (+70.1% YoY). On the balance sheet, XLO closed FY2025 with $154.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $43.8M | -$35.0M | -$5.0M | -$5.5M | $154.7M | — |
| FY2024 (FY) | 2024-12-31 | $6.3M | -$58.2M | -$18.4M | -$18.4M | $71.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$76.4M | -$68.6M | -$68.6M | — | — |
As of 2026-11-02, Xilio Therapeutics Inc. (NASDAQ: XLO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $7.77 (-3.00% 1D, market cap $51.1M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, XLO ranks #928 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XLO carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GANX (Gain Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $51.9M) and IBIO (iBio Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $52.3M). Among the 5-stock peer group, XLO leads on earnings multiple (N/A) while XLO leads on capital efficiency (-35.0% ROIC).
Per XLO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001840233), Xilio Therapeutics Inc. generated $43.8M in revenue (+589.9% YoY), -$35.0M in net income, and -$5.5M in free cash flow against $154.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
XLO last traded at $7.77 (-3.00% on volume of 2,708 shares), positioning the stock -11.70% below its 50-day simple moving average ($8.80) and -8.48% below its 200-day simple moving average ($8.49). Across its 52-week range of $6.47 to $12.32, XLO sits at the 22.2% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.80 to $8.74).
Why XLO Stock dropped -3.00% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).